Abstract: The present invention relates to a fusion protein in which transferrin is peptide-bonded to a terminal of a granulocyte-colony stimulating factor (G-CSF) protein or a G-CSF mutant protein in which the 116th threonine is substituted with cysteine in the amino acid sequence of the G-CSF. Specifically, the granulocyte-colony stimulating factor (G-CSF) mutant protein of the present invention or the transferrin fusion protein thereof displays a significantly increased specific activity and blood stability, compared with the conventional human G-CSF, and has a higher purification efficiency than the conventional PEGylated G-CSF characterized by the extended half-life, so that it can be advantageously used for preventing or treating ischemic diseases or neutropenia.
Type:
Grant
Filed:
September 19, 2019
Date of Patent:
August 23, 2022
Assignee:
PANACEA INC.
Inventors:
Jeong-Hyeok Yoon, Byung-Ha Chang, Bong-Seok Jin, Ji Young Bae, Soon Nam Kim, Kyeong Su Park, Yeong kyu Park, Hanjo Kim, Youngju Seo, Wooseong Jeong, KyungTae Kang
Abstract: The present invention relates to methods for the recombinant expression of chlamydia major outer membrane protein (MOMP) comprising transforming a population of E. coli host cells with an expression vector comprising a nucleic acid molecule that encodes chlamydia MOMP and encodes a leader sequence for targeting the MOMP to the outer membrane of the cell, wherein the nucleic acid molecule is operatively linked to a promoter. The method of the invention allows expression of MOMP in the outer membrane of the cell, which leads to protein folding that is more like native MOMP relative to a MOMP protein that is expressed intracellularly. Also provided by the invention are uses of the recombinant MOMP in pharmaceutical compositions and methods for the treatment and/or prophylaxis of chlamydia infection and/or the effects thereof.
Type:
Grant
Filed:
June 8, 2020
Date of Patent:
August 9, 2022
Assignee:
Merck Sharp & Dohme LLC
Inventors:
Lan Zhang, Zhiyun Wen, Craig T. Przysiecki, Ping Qiu
Abstract: The present invention relates to a monoclonal antibody platform designed to be coupled to therapeutic peptides to increase the half-life of the therapeutic peptide in a subject. The invention also relates to pharmaceutical compositions and methods for use thereof.
Type:
Grant
Filed:
August 21, 2020
Date of Patent:
August 2, 2022
Assignee:
Janssen Pharmaceutica NV
Inventors:
Mark Macielag, Raymond J. Patch, Rui Zhang, Martin A. Case, Shamina M. Rangwala, James N. Leonard, Raul C. Camacho, Michael J. Hunter, Katharine E. D'Aquino, Wilson Edwards, Ronald V. Swanson, Wenying Jian, Yue-Mei Zhang, Mark J. Wall, Ellen Chi
Abstract: An isolated bacterial strain Bacillus subtilis 281 or a functional homolog of same is provided. A sample has been deposited as KCTC 13468BP at the Korean Collection for Type Cultures, wherein the isolated microbial strain is purified to a level of at least 99%. Also provided are methods of using the isolated bacterial strain or the functional homolog of same.
Type:
Grant
Filed:
September 13, 2020
Date of Patent:
July 26, 2022
Assignee:
Better Air International Limited
Inventors:
Wilhelm H. Holzapfel, Yosep Ji, Yuli Horesh, Michael Hoffman, Shimrit Laor
Abstract: Methods of formulating live biotherapeutics are disclosed in which a deficiency or excess of a specific bacterial strain in a person's microbiome is identified by comparing a gene-specific characterization of the person's microbiome against a comprehensive, non-redundant reference gene catalog, and the biotherapeutic is formulated by selecting bacteria to address the deficiency or excess. Embodiments include the formulation of live biotherapeutics for improving the health of a person's vaginal microbiome, i.e. using a vaginal reference gene catalog, and may be suitable for ameliorating, treating, or preventing a malignancy such as a cancer of the female genitourinary system.
Type:
Grant
Filed:
April 6, 2021
Date of Patent:
July 19, 2022
Assignee:
University of Maryland, Baltimore
Inventors:
Jacques Ravel, Michael France, Lindsay Rutt, Bing Ma
Abstract: The present invention relates, in part, to chimeric proteins comprising at least one targeting moiety that recognizes and binds SIRP1? and their use as diagnostic and therapeutic agents. The present invention further relates to pharmaceutical compositions comprising the chimeric proteins and their use in the treatment of various diseases.
Abstract: An isolated bacterial strain Bacillus subtilis 3 or a functional homolog of same is provided. A sample has been deposited as KCTC 13467BP at the Korean Collection for Type Cultures, wherein the isolated microbial strain is purified to a level of at least 99%. Also provided are methods of using the isolated bacterial strain or the functional homolog of same.
Type:
Grant
Filed:
September 14, 2020
Date of Patent:
July 12, 2022
Assignee:
Better Air International Limited
Inventors:
Wilhelm H. Holzapfel, Yosep Ji, Yuli Horesh, Michael Hoffman, Shimrit Laor
Abstract: The problem to be solved is to provide a humanized anti-IL-6 receptor antibody MRA-containing formulation which is suitable for subcutaneous administration, wherein dimerization or deamidation is prevented during long-term storage. The present application is directed to a stable antibody-containing liquid formulation characterized by containing arginine and histidine buffer. A method of inhibiting deamidation or dimerization of such an antibody in a concentrated liquid formulation includes histidine buffer in the liquid formulation.
Type:
Grant
Filed:
April 27, 2021
Date of Patent:
June 14, 2022
Assignees:
CHUGAI SEIYAKU KABUSHIKI KAISHA, HOFFMANN-LA ROCHE INC.
Inventors:
Toshiyuki Morichika, Daisuke Kameoka, Yoshimi Imaeda, Terutoshi Maeda, Oliver Boris Stauch
Abstract: Provided herein are variant CD80 polypeptides, immunomodulatory proteins comprising variant CD80 polypeptides, and nucleic acids encoding such proteins. The immunomodulatory proteins provide therapeutic utility for a variety of immunological and oncological conditions. Compositions and methods for making and using such proteins are provided.
Abstract: The invention relates to methods of modulating immune cells in a patient by altering microbiota of the patient. The invention also relates to methods of modulating treatments or therapies in a subject organism by altering microbiota of the subject. The invention also relates to cell populations, systems, arrays, cells, RNA, kits and other means for effecting this. In an example, advantageously selective targeting of a particular species in a human gut microbiota using guided nucleic acid modification is carried out to effect the alteration.
Abstract: We provide new monoclonal antibody inhibitors of coagulases staphylocoagulase and vWbp for treatment of S. aureus. The monoclonal antibodies are useful in targeting the SC N-terminus of SC and vWbp (respectively) and inhibiting prothrombin activation. The monoclonal antibodies are able to bind to and interfere with, modulate, and/or inhibit the binding interactions between the coagulase protein and its ligand protein prothrombin in blood and tissues. The antibodies are effective in inhibiting the activation of prothrombin.
Abstract: Provided is a use of Butyribacter intestini in preventing and/or treating inflammation-related diseases. Specifically, in the present disclosure, it was firstly discovered that Butyribacter intestini has the function of preventing and/or treating inflammation-related diseases (for example, inflammatory bowel disease, such as ulcerative colitis, gastritis, and common enteritis; and rheumatoid arthritis).
Abstract: The present disclosure includes methods and components for production of valuable industrial compounds in yeast. In an embodiment, the present invention provides a nucleic acid construct with increased stability for gene expression or gene editing comprising: a nucleic acid sequence encoding one or more of SEQ ID NO: 1-8 (CENs 1-8); and one or more regulatory elements functional in a yeast cell. In an embodiment of the present invention the nucleic acid constructs are vectors, preferably episomal vectors. High expression promoters, as well as methods for increasing production of compounds such as aromatics are disclosed.
Type:
Grant
Filed:
July 28, 2020
Date of Patent:
May 17, 2022
Assignee:
Iowa State University Research Foundation, Inc.
Inventors:
Zengyi Shao, Mingfeng Cao, Miguel Suastegui, Meirong Gao
Abstract: Novel combination therapies involving nitroxoline, its analogue or pharmaceutically acceptable salt thereof with at least one additional anti-cancer chemotherapy or immunotherapy agent are described. Related kits, pharmaceutical compositions and methods of production arlinee also described.
Abstract: Disclosed is the attenuated Salmonella typhi vaccine Ty21a utilized as a vector for Shigella and/or enterotoxogenic E. coli genes stably integrated in the Ty21a chromosome. These genes include a heterologous Shigella sonnei O-antigen biosynthetic gene region that comprises the wzz gene and expresses Shigella sonnei form 1 O-antigen, as well as a heterologous acid resistance biosynthetic gene system comprising a YbaS gene, which enables increased stability of the Ty21a vector at pH 2.5 relative to Ty21a without the integrated acid resistance biosynthetic gene system.
Type:
Grant
Filed:
June 10, 2020
Date of Patent:
May 10, 2022
Assignee:
Protein Potential, LLC
Inventors:
Yun Wu, Dennis J. Kopecko, B. Kim Lee Sim, Stephen L. Hoffman
Abstract: The present invention provides, among other things, a method of treating a subject with infection-induced hyperinflammation comprising administering to the subject a granulocyte-macrophage colony-stimulating factor (GM-CSF) antagonist at a therapeutically effective dose and an administration interval for a treatment period sufficient to improve, stabilize or reduce one or more symptoms of hyperinflammation. The present invention also provides, among other things, a method of inhibiting or reducing cytokine release syndrome (CRS) or acute respiratory distress syndrome (ARDS) in a subject comprising administering to the subject a granulocyte-macrophage colony-stimulating factor (GM-CSF) antagonist at a therapeutically effective dose and an administration interval for a treatment period sufficient to improve, stabilize or reduce one or more symptoms of CRS or ARDS.
Type:
Grant
Filed:
May 19, 2021
Date of Patent:
May 10, 2022
Inventors:
Joe Pirrello, John Paolini, Eben Tessari
Abstract: The present invention provides a fusion polypeptide comprising a first domain and a second domain, wherein the first domain comprises a polypeptide ligand which binds to a cell surface-associated antigen and the second domain comprises aglycosylated interferon ? 2b (IFN?2b) having a sequence of SEQ ID NO: 1 or SEQ ID NO: 2. The aglycosylated IFN?2b further comprises one or more amino acid substitutions or deletions which attenuate the activity of the aglycosylated IFN?2b.
Type:
Grant
Filed:
December 11, 2019
Date of Patent:
May 3, 2022
Assignee:
Teva Pharmaceuticals Australia Pty Ltd
Inventors:
Collette Behrens, Anthony Doyle, Adam Clarke, Matthew Pollard, Teresa Domagala
Abstract: The present invention relates to active form specific anti-Rho GTPase conformational single domain antibodies and their uses in particular in the therapeutic and diagnostic fields. In particular, the present invention relates to a single domain antibody wherein the amino acid sequences of CDR1-IMGT, CDR2-IMGT and CDR3-IMGT have at least 90% of identity with the amino acid sequences of the CDR1-IMGT, CDR2-IMGT and CDR3-IMGT of the H12, B6, 4P75, 4SP1, 4SNP36, 4SNP61, 5SP10, 5SP11, 5SP58, 5SNP47, 5SNP48, 5SNP65, B20, B15, B5, B71, E3, A6, G12, NB61, 212B, 111B or 404F (hs2dAb) single domain antibody which are defined in Table B.
Type:
Grant
Filed:
December 4, 2019
Date of Patent:
May 3, 2022
Assignees:
INSERM (Institut National de la Santéet de la Recherche Médicale), UniversitéPaul Sabatier Toulouse III, Institut Claudius Regaud
Inventors:
Aurelien Olichon, Laura Keller, Gilles Favre, Nicolas Bery, Patrick Chinestra